Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Daiichi Sankyo Ltd ADR (OP: DSNKY )

29.81 +1.03 (+3.58%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,351
Open 29.87
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 28.78
Today's Range 28.67 - 29.90
52wk Range 26.47 - 42.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
Via Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga

Performance

YTD
+10.04%
+10.04%
1 Month
-6.90%
-6.90%
3 Month
-26.05%
-26.05%
6 Month
-14.51%
-14.51%
1 Year
+10.37%
+10.37%

More News

Read More
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Via Benzinga
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
Via InvestorPlace
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Via Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Via Benzinga
Exposures Product Safety
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
Via InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
Via Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Via Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Via Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Via Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Via The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Via Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.